CLAIM #37100 · Eli Lilly and Company (LLY) · 2025Q4 earnings call · Feb 4, 2026 · due Jun 30, 2026
“We're excited to launch orforglipron soon with the entry price being similar to oral semaglutide.”
Ilya Yuffa · President of Lilly USA and Global Customer Capabilities
PENDING
graded after results covering Jun 30, 2026 are reported
Verify independently
SEC filings for LLY ↗ · Claim quote is verbatim from the 2025Q4 earnings call.